18 February, 2021
“The fourth quarter of 2020 was one of the most eventful in Nanexa’s history. We received a GMP certificate for drug manufacturing and a clinical trial permit for our NEX-18 project. We signed a collaboration agreement with Applied Materials and an investment agreement with Applied Ventures and, after careful evaluation, we decided shortly after the end of the quarter to choose lenalidomide for our NEX-20 project.” David Westberg, CEO Nanexa
Nanexa AB (”Nanexa” or ”the Company”) today announced the result of the use of warrants of series TO2, which were issued in connection with the Company’s rights issue in February 2020. The result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2.
2 February, 2021
Nanexa invites to a webcast hosted by CEO David Westberg, Chairman Göran Ando, and board member Bengt Gustavsson, who will give an update and talk about their view on Nanexa and the current project portfolio.
28 January, 2021
Nanexa AB (publ) today announced that the company has signed an evaluation agreement, a so-called Material Transfer and Feasibility Study Agreement, with a non-disclosed European biotech company. The company is running a development project within the cardiovascular field, where PharmaShell®, as the drug delivery system, can enable an injectable product that releases the drug substance during 1-2 weeks.
26 January, 2021
Nanexa AB (publ) today announced that the company has received a so-called “Notice of Allowance” for a patent application in Canada. The patent application refers to PharmaShell® administered in every conceivable way, for example by parenteral injection, inhalation or by oral administration.
13 January, 2021
Nanexa AB today announces that the company has chosen to develop a long-acting formulation of lenalidomide for the treatment of multiple myeloma. NEX-20 will be the company’s second own product project.
12 January, 2021
On December 17, 2020, Nanexa AB (publ) (“Nanexa” or “the Company”) announced that the Company has entered into an investment agreement with Applied Ventures, LLC (“Applied Ventures”) through which Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. Today, January 12, 2021, Nanexa’s Board of Directors has decided, with the support of the authorization received at the Annual General Meeting on June 2, 2020, to issue 686,492 shares and 3,558,278 warrants (the “Directed Issue”) to Applied Ventures. In accordance with the investment agreement, the subscription price for the shares in the Directed Issue has been set at the volume-weighted average price (“VWAP”) during the period December 22, 2020 through January 11, 2021 with a deduction of five percent, corresponding to SEK 11.99 per share.
17 December, 2020
Nanexa AB (publ) today announced that the company has entered into an investment agreement with Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., whereby Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. USD 1 million will be invested in January 2021 and additional investments of up to USD 2 million are planned later in 2021. The investment will be made through a directed issue to Applied Ventures of a mix of shares and share warrants decided upon by Nanexa with support of the authorization of the Annual General Meeting held on June 2, 2020 (the “Directed Issue”).
Nanexa AB (publ) today announced that the company has entered into a collaboration agreement with the leading materials engineering solutions company Applied Materials, Inc. in order to establish a scaled-up GMP production site for ALD-coated pharmaceuticals located at Nanexa’s facilities in Uppsala.
10 December, 2020
Nanexa AB (publ) today announced that the company has received permission to start the clinical trial for the drug candidate NEX-18 by the Swedish Medical Products Agency, Läkemedelsverket.
Nanexa in late stage partnering and investment negotiations with Applied Materials and Applied Ventures
27 November, 2020
Nanexa AB (publ) today announces that the company is in late stage negotiations about entering into a joint development agreement with the world leading materials engineering solutions company Applied Materials Inc.
24 March, 2020
The trading in Nanexa AB''s subscription options NANEXA TO2 will take place from April 1, 2020.
Please see the company''s webpage for the full terms of the subscription option.
23 March, 2020
Last day of trading in the company''s paid subscribed unit, NANEXA BTU, is March 26, 2020.?
Information about the paid subscribed unit:
Shortname: NANEXA BTU
FISN: NANEXA/UT 4 AK + 2 TO
Last day of trading: March 26,
3 February, 2020
The last day of trading in the company"s shares NANEXA including the right to receive unit rights is February 5, 2020. The first day excluding the right to obtain the rights is February 6,
23 January, 2019
Sista dag för handel med bolagets teckningsoption serie TO 1, är den 30 januari 2019.